These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30724632)

  • 21. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
    Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
    Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
    Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
    BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.
    Engelmann D; Pützer BM
    Drug Resist Updat; 2010; 13(4-5):119-31. PubMed ID: 20675184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer.
    Matsumoto A; Hayashida T; Takahashi M; Jinno H; Kitagawa Y
    Mol Med Rep; 2018 Jul; 18(1):958-964. PubMed ID: 29845287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. E2F1 enhances 8-chloro-adenosine-induced G2/M arrest and apoptosis in A549 and H1299 lung cancer cells.
    Duan HY; Cao JX; Qi JJ; Wu GS; Li SY; An GS; Jia HT; Cai WW; Ni JH
    Biochemistry (Mosc); 2012 Mar; 77(3):261-9. PubMed ID: 22803943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers.
    Fenner F; Goody D; Protzel C; Erbersdobler A; Richter C; Hartz JM; Naumann CM; Kalthoff H; Herchenröder O; Hakenberg OW; Pützer BM
    Eur Urol Focus; 2018 Jul; 4(4):599-607. PubMed ID: 28753861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Setting the bar higher for ovarian cancer survival.
    Jenks S
    J Natl Cancer Inst; 2014 Feb; 106(2):dju037. PubMed ID: 24511114
    [No Abstract]   [Full Text] [Related]  

  • 28. Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin.
    Van Den Broeck A; Nissou D; Brambilla E; Eymin B; Gazzeri S
    Carcinogenesis; 2012 Feb; 33(2):320-5. PubMed ID: 22159227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of p14ARF by E2F1 contributes to 8-chloro-adenosine-induced apoptosis in human lung cancer H1299 cells.
    Li WJ; Gu YY; Zhang HJ; Zhou J; Jia HT
    Chemotherapy; 2009; 55(5):335-43. PubMed ID: 19641316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unfolded protein response mediated JNK/AP-1 signal transduction, a target for ovarian cancer treatment.
    Zheng GF; Cai Z; Meng XK; Zhang Y; Zhu W; Pang XY; Dou L
    Int J Clin Exp Pathol; 2015; 8(6):6505-11. PubMed ID: 26261528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting E2F1 death signaling: opposing role in cancer control and neurodegeneration.
    Pützer BM
    Discov Med; 2006 Jun; 6(33):123-7. PubMed ID: 17234147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ovarian cancer drug market.
    Bamford J; Webster RM
    Nat Rev Drug Discov; 2017 Jul; 16(7):451-452. PubMed ID: 28546548
    [No Abstract]   [Full Text] [Related]  

  • 34. E2F1: a promising regulator in ovarian carcinoma.
    Zhan L; Zhang Y; Wang W; Song E; Fan Y; Wei B
    Tumour Biol; 2016 Mar; 37(3):2823-31. PubMed ID: 26749284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.
    Goyeneche AA; Carón RW; Telleria CM
    Clin Cancer Res; 2007 Jun; 13(11):3370-9. PubMed ID: 17545545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting endothelin-1 receptor/β-arrestin1 network for the treatment of ovarian cancer.
    Rosanò L; Cianfrocca R; Sestito R; Tocci P; Di Castro V; Bagnato A
    Expert Opin Ther Targets; 2017 Oct; 21(10):925-932. PubMed ID: 28758529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
    Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
    Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.
    Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Rogowski W; Domagala W
    Pathol Oncol Res; 2016 Jul; 22(3):601-8. PubMed ID: 26831819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. E2F1-regulated DROSHA promotes miR-630 biosynthesis in cisplatin-exposed cancer cells.
    Cao JX; Li SY; An GS; Mao ZB; Jia HT; Ni JH
    Biochem Biophys Res Commun; 2014 Jul; 450(1):470-5. PubMed ID: 24909689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.